Oxford CPD on anticounterfeiting

A professional development course at the University of Oxford on counterfeits and strategies to counter them:

Suspect Counterfeit Detection, Avoidance and Mitigation
with Case Histories for Nonconforming ESD Packaging Materials Used in the Shipment of Electronic Parts,

Includes a review of how semiconductor and medical device packaging countermeasures utilize advanced material solutions.

Especially of interest to Digital Drugs this part:

Anti-Counterfeiting Measures for Packaging, […]

A decision support tool for warfarin prescribing

Anna-Karin Hamberg, Jacob Hellman, Jonny Dahlberg, E Niclas Jonsson and Mia Wadelius (2015)
A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children
BMC Medical Informatics and Decision Making 2015, 15:7

Based on population based Pharmacokinetic-pharmacodynamic (PK/PD) model of warfarin.
The tool is developed in Java.
“.. user enters information on body weight, age, baseline and target INR, and […]

On innovation, policies, economic returns – the cases of antibiotics , new and transformative drugs

In the current issue of Health Affairs :

February 2015; Volume 34, Issue 2 Biomedical Innovation

Outterson, K., J. H. Powers, G. W. Daniel and M. B. McClellan (2015). “Repairing The Broken Market For Antibiotic Innovation.” Health Affairs 34(2): 277-285.

“…Good public health practices curb inappropriate antibiotic use, making return on investment challenging in payment systems based on sales volume. We […]

‘Everyday drug diversions’ – on people’s everyday use of drugs

Vrecko, S. “Everyday drug diversions: A qualitative study of the illicit exchange and non-medical use of prescription stimulants on a university campus.” Social Science & Medicine (in the press).

“This article investigates everyday experiences and practises that are associated with processes of pharmaceuticalization and with practices of ‘drug diversion’—that is, the illicit exchange and non-medical use of prescription […]

February 4th, 2015|Medicines|0 Comments|

On the rise of the “translational state” – The State commitment to accelerating the commercial translation of biomedical research

Hogarth, S. “Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics.” Social Science & Medicine. Available online 15 January 2015 – In Press, Accepted Manuscript

“By 2004 the FDA had emerged as a champion of pharmacogenomics as an exemplar for novel approaches to drug development. This was made clear in 2004 when […]

On genetics and electronic health record

A Special Issue of the Genetics in Medicine journal on genetics and electronic health record

Volume 15, Issue 10 (October 2013)

Among others, in this issue:

Integration of genomics into the electronic health record: mapping terra incognita
Joseph L. Kannry MD and Marc S. Williams MD

“… To date, no commercial EHR system has been described that systematically integrates genetic or genomic […]

Molecular profiling for deciding therapy—the French initiative

Nowak, F., J.-C. Soria and F. Calvo (2012). “Tumour molecular profiling for deciding therapy – the French initiative.” Nat Rev Clin Oncol 9(8): 479-486.

From the abstract:

In France a national network of 28 regional molecular genetics centres. Selected molecular tests, free of charge, to all patients and “specific programme has also been implemented to anticipate the launch […]

Intelligent Potato Pills

Proteus’ intelligent pill, named Helius, is designed to be swallowed with medicines. The embedded microprocessor is powered by acid in the stomach in same way as a potato battery. The pill  can then monitor patients’ medication use, compliance with doctors’ instructions or report vital signs. Read more here in a Nature article from 2012.

Definitions: Efficacy, Effectiveness, Efficiency

Borrowing from
John Marley, Professor, Department of General Practice, University of Adelaide, Adelaide
Aust Prescr 2000;23:114-5

Efficacy –  can a treatment work?
As in a clinical trial, i.e. in ideal circumstance of a controlled trial population.

Effectiveness – ‘the extent to which a drug achieves its intended effect in the usual clinical setting’

Effectiveness “can be evaluated through observational studies of real practice”; local and […]

On medicines: for risk markers, not factors, for disease …

… to remember to explore further:

“So much of this ‘evidence’ is for drug treatment, especially comparing one drug against another. We now have enough research evidence that shows that many of the ‘things’ doctors advise (drug) treatment for, are but markers of an underlying problem. Sadly, these are mostly for the most common of problems – risk markers, not […]

August 7th, 2014|Medicines|0 Comments|